Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 3/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | IDH1 | O75874 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.31 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701769 | 0.79 | KDM4E (0.38) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 | |
| SCHEMBL7010909 | 0.74 | PDE3B (0.35) | PDE3BPDE3ASMN1; SMN2HSD17B10DHFR | |
| SCHEMBL9846258 | 0.71 | TYMP (0.39) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 | |
| SCHEMBL5197709 | 0.69 | TYMP (0.38) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 | |
| SCHEMBL7378429 | 0.67 | KDM4E (0.48) | KDM4EHTTMAPTALDH1A1 | |
| SCHEMBL6024307 | 0.65 | PDE3B (0.44) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 | |
| SCHEMBL19261715 | 0.64 | PDE3B (0.42) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 | |
| SCHEMBL9846085 | 0.61 | POLB (0.34) | KDM4EPDE3BPDE3AIDH1HPGD | |
| SCHEMBL3588189 | 0.60 | IDH1 (0.46) | IDH1ALDH1A1MPO | |
| SCHEMBL11650846 | 0.60 | HSD17B10 (0.41) | KDM4EPDE3BPDE3ASMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1073637-B1 | 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES | CENTRE NAT RECH SCIENT (FR) | 2006-08-02 | — | — | EP | disclosed |
| US-6683079-B2 | REVERSE TRANSCRIPTASE INHIBITORS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2004-01-27 | — | — | US | disclosed |
| US-20030125340-A1 | Reverse transcriptase inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENT. (FR) | 2003-07-03 | — | — | US | disclosed |
| US-6451822-B1 | 3-(Amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of HIV related diseases | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2002-09-17 | — | — | US | disclosed |
| EP-1073637-A1 | 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055676-A1 | 3-(AMINO- OR AMINOALKYL)PYRIDINONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF HIV RELATED DISEASES | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125340-A1 | Reverse transcriptase inhibitors | QTRT1, RTF2, POLR1A | KDM4E 534/4885PDE3B 1314/4885PDE3A 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.